Patent classifications
A61K31/497
SELECTIVE OCTAHYDRO-CYCLOPENTA[C]PYRROLE NEGATIVE MODULATORS OF NR2B
Compounds that selectively negatively modulate NMDA receptors containing an NR1/NR2B subunit, pharmaceutical compositions comprising the compounds, and methods of treating a disease using the compounds are disclosed.
SELECTIVE OCTAHYDRO-CYCLOPENTA[C]PYRROLE NEGATIVE MODULATORS OF NR2B
Compounds that selectively negatively modulate NMDA receptors containing an NR1/NR2B subunit, pharmaceutical compositions comprising the compounds, and methods of treating a disease using the compounds are disclosed.
Carboxamide-pyrimidine derivatives as SHP2 antagonists
The invention relates to carboxamide-pyrimidine derivatives of the general formula I, ##STR00001##
or a pharmaceutically acceptable salt thereof, and the use of the compounds of the present invention for the treatment of hyperproliferative diseases and disorders in mammals, especially humans, and pharmaceutical compositions containing such compound.
Carboxamide-pyrimidine derivatives as SHP2 antagonists
The invention relates to carboxamide-pyrimidine derivatives of the general formula I, ##STR00001##
or a pharmaceutically acceptable salt thereof, and the use of the compounds of the present invention for the treatment of hyperproliferative diseases and disorders in mammals, especially humans, and pharmaceutical compositions containing such compound.
PD-1/PD-L1 INHIBITORS
- Evangelos Aktoudianakis ,
- Aesop Cho ,
- Zhimin Du ,
- Michael Graupe ,
- Lateshkumar Thakorlal Lad ,
- Paulo A. Machicao Tello ,
- Jonathan William Medley ,
- Samuel E. Metobo ,
- Prasenjit Kumar Mukherjee ,
- Devan Naduthambi ,
- Eric Q. Parkhill ,
- Barton W. Phillips ,
- Scott Preston Simonovich ,
- Neil H. Squires ,
- Peiyuan Wang ,
- William J. Watkins ,
- Jie Xu ,
- Kin Shing Yang ,
- Christopher Allen Ziebenhaus
Compounds of Formula (I), methods of using said compounds singly or in combination with additional agents and compositions of said compounds for the treatment of cancer are disclosed.
PD-1/PD-L1 INHIBITORS
- Evangelos Aktoudianakis ,
- Aesop Cho ,
- Zhimin Du ,
- Michael Graupe ,
- Lateshkumar Thakorlal Lad ,
- Paulo A. Machicao Tello ,
- Jonathan William Medley ,
- Samuel E. Metobo ,
- Prasenjit Kumar Mukherjee ,
- Devan Naduthambi ,
- Eric Q. Parkhill ,
- Barton W. Phillips ,
- Scott Preston Simonovich ,
- Neil H. Squires ,
- Peiyuan Wang ,
- William J. Watkins ,
- Jie Xu ,
- Kin Shing Yang ,
- Christopher Allen Ziebenhaus
Compounds of Formula (I), methods of using said compounds singly or in combination with additional agents and compositions of said compounds for the treatment of cancer are disclosed.
Heterocyclic compounds and uses thereof
Heterocyclic entities that modulate PI3 kinase activity, pharmaceutical compositions containing the heterocyclic entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein.
Heterocyclic compounds and uses thereof
Heterocyclic entities that modulate PI3 kinase activity, pharmaceutical compositions containing the heterocyclic entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein.
Compounds and compositions for the inhibition of NAMPT
The present invention relates to compounds and compositions for the inhibition of NAMPT, their synthesis, applications and antidotes. An illustrative compound of the invention is shown below: ##STR00001##
Compounds and compositions for the inhibition of NAMPT
The present invention relates to compounds and compositions for the inhibition of NAMPT, their synthesis, applications and antidotes. An illustrative compound of the invention is shown below: ##STR00001##